Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Current Leases (2019 - 2025)

ProQR Therapeutics' Current Leases history spans 6 years, with the latest figure at $1.8 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 7.4% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 7.4% increase, with the full-year FY2025 number at $1.8 million, up 7.4% from a year prior.
  • Current Leases hit $1.8 million in Q4 2025 for ProQR Therapeutics, up from $1.7 million in the prior quarter.
  • Over the last five years, Current Leases for PRQR hit a ceiling of $1.8 million in Q4 2025 and a floor of -$1.6 billion in Q1 2021.
  • Historically, Current Leases has averaged -$267.4 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Current Leases: fell 19.36% in 2022 and later increased 22.72% in 2023.
  • Tracing PRQR's Current Leases over 5 years: stood at $1.8 million in 2021, then dropped by 19.36% to $1.4 million in 2022, then rose by 22.72% to $1.7 million in 2023, then dropped by 3.57% to $1.7 million in 2024, then increased by 7.4% to $1.8 million in 2025.
  • Business Quant data shows Current Leases for PRQR at $1.8 million in Q4 2025, $1.7 million in Q4 2024, and $1.7 million in Q4 2023.